Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CXCR1 | P25024 | 4/20 | 0.45 |
| ▸ | CXCR2 | P25025 | 4/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12189636 | 0.84 | MEN1 (0.45) | DGAT1PTPN1MEN1POLBKMT2A | |
| SCHEMBL12173151 | 0.84 | CXCR1 (0.47) | DGAT1MEN1KMT2ACXCR1CXCR2 | |
| SCHEMBL12189646 | 0.84 | PTPN1 (0.51) | DGAT1PTPN1MEN1POLBKMT2A | |
| SCHEMBL12835495 | 0.84 | FAAH (0.56) | NR1H4FAAH | |
| SCHEMBL12189571 | 0.84 | FAAH (0.56) | NR1H4FAAH | |
| SCHEMBL12189643 | 0.84 | FAAH (0.56) | NR1H4FAAH | |
| SCHEMBL12189418 | 0.81 | SMN1; SMN2 (0.58) | PTPN1MEN1POLBKMT2ANR1H4 | |
| SCHEMBL12189460 | 0.80 | PKM (0.57) | DGAT1PTPN1MEN1POLBKMT2A | |
| SCHEMBL12173098 | 0.80 | CXCR2 (0.54) | MEN1POLBKMT2ACXCR1CXCR2 | |
| SCHEMBL12173065 | 0.76 | KCNQ3 (0.59) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232150-A1 | PHTHALANILATE COMPOUNDS AND METHODS OF USE | University of Nortre Dame du Lac | 2012-09-13 | — | — | US | disclosed |
| WO-2011026107-A1 | PHTHALANILATE COMPOUNDS AND METHODS OF USE | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232150-A1 | PHTHALANILATE COMPOUNDS AND METHODS OF USE | MPO, ALPI, NQO1 | DGAT1 2262/4885PTPN1 1324/4885MEN1 2365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.